137 related articles for article (PubMed ID: 38847867)
1. Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization.
DeTemple VK; Walter A; Bredemeier S; Gutzmer R; Schaper-Gerhardt K
Arch Dermatol Res; 2024 Jun; 316(7):341. PubMed ID: 38847867
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Blauvelt A; Kempers S; Lain E; Schlesinger T; Tyring S; Forman S; Ablon G; Martin G; Wang H; Cutler DL; Fang J; Kwan MR;
N Engl J Med; 2021 Feb; 384(6):512-520. PubMed ID: 33567191
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis.
Yavel R; Overcash JS; Cutler D; Fang J; Zhi J
Clin Pharmacol Drug Dev; 2022 Mar; 11(3):397-405. PubMed ID: 34783452
[TBL] [Abstract][Full Text] [Related]
4. 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.
Dao DD; Sahni VN; Sahni DR; Balogh EA; Grada A; Feldman SR
Ann Pharmacother; 2022 Apr; 56(4):494-500. PubMed ID: 34301153
[TBL] [Abstract][Full Text] [Related]
5. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
Kempers S; DuBois J; Forman S; Poon A; Cutler E; Wang H; Cutler D; Fang J; Kwan R
J Drugs Dermatol; 2020 Nov; 19(11):1093-1100. PubMed ID: 33196758
[TBL] [Abstract][Full Text] [Related]
6. Tirbanibulin for the Treatment of Actinic Keratosis: A Review.
Miller AC; Adjei S; Temiz LA; Tyring SK
Skin Therapy Lett; 2022 Jul; 27(4):4-7. PubMed ID: 35857917
[TBL] [Abstract][Full Text] [Related]
7. Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action.
Schlesinger T; Stockfleth E; Grada A; Berman B
Clin Cosmet Investig Dermatol; 2022; 15():2495-2506. PubMed ID: 36415541
[TBL] [Abstract][Full Text] [Related]
8. Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study.
Li Pomi F; Vaccaro M; Pallio G; Rottura M; Irrera N; Borgia F
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399512
[No Abstract] [Full Text] [Related]
9. Focused update: Guidelines of care for the management of actinic keratosis.
Eisen DB; Dellavalle RP; Frazer-Green L; Schlesinger TE; Shive M; Wu PA
J Am Acad Dermatol; 2022 Aug; 87(2):373-374.e5. PubMed ID: 35439607
[TBL] [Abstract][Full Text] [Related]
10. Plexin-B1 and semaphorin 4D cooperate to promote cutaneous squamous cell carcinoma cell proliferation, migration and invasion.
Cao J; Zhang C; Chen T; Tian R; Sun S; Yu X; Xiao C; Wang G; Liu Y; Fu M; Li W
J Dermatol Sci; 2015 Aug; 79(2):127-36. PubMed ID: 26051877
[TBL] [Abstract][Full Text] [Related]
11. Tirbanibulin: First Approval.
Markham A; Duggan S
Drugs; 2021 Mar; 81(4):509-513. PubMed ID: 33713299
[TBL] [Abstract][Full Text] [Related]
12. Profile of Tirbanibulin for the Treatment of Actinic Keratosis.
Berman B; Grada A; Berman DK
J Clin Aesthet Dermatol; 2022 Oct; 15(10 Suppl 1):S3-S10. PubMed ID: 36408375
[TBL] [Abstract][Full Text] [Related]
13. Tirbanibulin: A New Topical Therapy for Actinic Keratoses With a Novel Mechanism of Action and Improved Ease of Use.
Gilchrest BA
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1126-1129. PubMed ID: 34612001
[No Abstract] [Full Text] [Related]
14. Pre-mRNA processing factor 3 enhances the progression of keratinocyte-derived cutaneous squamous cell carcinoma by regulating the JAK2/STAT3 pathway.
Zuo S; Li X; Bao W; Li S
Sci Rep; 2020 Jun; 10(1):8863. PubMed ID: 32483193
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells.
Wang Y; Li Z; Teng M; Liu J
Int J Med Sci; 2021; 18(12):2705-2715. PubMed ID: 34104103
[TBL] [Abstract][Full Text] [Related]
16. Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review.
Mohney L; Singh R; Grada A; Feldman S
J Drugs Dermatol; 2022 Jan; 21(1):60-65. PubMed ID: 35005863
[TBL] [Abstract][Full Text] [Related]
17. Single-cell sequencing highlights heterogeneity and malignant progression in actinic keratosis and cutaneous squamous cell carcinoma.
Zou DD; Sun YZ; Li XJ; Wu WJ; Xu D; He YT; Qi J; Tu Y; Tang Y; Tu YH; Wang XL; Li X; Lu FY; Huang L; Long H; He L; Li X
Elife; 2023 Dec; 12():. PubMed ID: 38099574
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm
DuBois J; Jones TM; Lee MS; Falqués M; Kiyasova V; Jiménez G; Otero R; Jansat JM; Aubets J; Forconi RJ
Clin Pharmacol Drug Dev; 2024 Feb; 13(2):208-218. PubMed ID: 38185925
[TBL] [Abstract][Full Text] [Related]
19. An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
Puizina-Ivić N; Sapunar D; Marasović D; Mirić L
Coll Antropol; 2008 Oct; 32 Suppl 2():61-5. PubMed ID: 19138009
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
